SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 406 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,021 | +33.7% | 88,315 | +89.6% | 0.41% | -1.2% |
Q2 2023 | $3,008 | -18.0% | 46,591 | -30.1% | 0.42% | +9.7% |
Q1 2023 | $3,667 | +46.1% | 66,661 | +72.3% | 0.38% | +79.7% |
Q4 2022 | $2,510 | -99.9% | 38,700 | -30.0% | 0.21% | +60.6% |
Q3 2022 | $1,918,000 | +25.4% | 55,300 | -16.8% | 0.13% | +23.4% |
Q2 2022 | $1,530,000 | +38.0% | 66,485 | +1.4% | 0.11% | +84.5% |
Q1 2022 | $1,109,000 | -70.3% | 65,550 | -46.5% | 0.06% | -62.8% |
Q4 2021 | $3,729,000 | +45.6% | 122,630 | +248.4% | 0.16% | +35.7% |
Q3 2021 | $2,562,000 | +359.1% | 35,200 | +85.3% | 0.12% | +342.3% |
Q2 2021 | $558,000 | -48.2% | 19,000 | +3.5% | 0.03% | -50.9% |
Q1 2021 | $1,077,000 | +16.4% | 18,364 | -73.5% | 0.05% | +20.5% |
Q4 2020 | $925,000 | +20.0% | 69,400 | +183.3% | 0.04% | -6.4% |
Q3 2020 | $771,000 | +4.8% | 24,500 | -15.2% | 0.05% | -4.1% |
Q2 2020 | $736,000 | -40.6% | 28,900 | -6.5% | 0.05% | -23.4% |
Q1 2020 | $1,239,000 | -40.7% | 30,901 | -31.6% | 0.06% | -50.0% |
Q4 2019 | $2,091,000 | +63.1% | 45,200 | -12.9% | 0.13% | +10.3% |
Q3 2019 | $1,282,000 | -56.6% | 51,900 | -36.9% | 0.12% | -57.7% |
Q2 2019 | $2,952,000 | +208.1% | 82,204 | +162.6% | 0.27% | +176.8% |
Q1 2019 | $958,000 | -27.8% | 31,300 | -36.3% | 0.10% | -21.4% |
Q4 2018 | $1,326,000 | -29.5% | 49,103 | -8.6% | 0.13% | -3.1% |
Q3 2018 | $1,880,000 | -55.0% | 53,703 | -37.0% | 0.13% | -61.0% |
Q2 2018 | $4,176,000 | +957.2% | 85,281 | +205.1% | 0.33% | +879.4% |
Q1 2018 | $395,000 | -49.5% | 27,955 | -59.1% | 0.03% | +6.2% |
Q4 2017 | $782,000 | -42.1% | 68,344 | -56.8% | 0.03% | -37.3% |
Q3 2017 | $1,350,000 | +64.8% | 158,136 | +28.7% | 0.05% | +70.0% |
Q2 2017 | $819,000 | +22.8% | 122,853 | -1.5% | 0.03% | +7.1% |
Q1 2017 | $667,000 | -91.6% | 124,755 | -80.1% | 0.03% | -90.3% |
Q4 2016 | $7,975,000 | -28.4% | 626,995 | -36.8% | 0.29% | -42.3% |
Q3 2016 | $11,145,000 | -24.3% | 992,710 | -29.4% | 0.50% | -33.3% |
Q2 2016 | $14,728,000 | +231.7% | 1,405,202 | +254.6% | 0.75% | +156.2% |
Q1 2016 | $4,440,000 | +36.2% | 396,281 | +7.0% | 0.29% | +60.4% |
Q4 2015 | $3,261,000 | – | 370,274 | – | 0.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |